Allouche Cyril

Avg. Two Year Performance

No purchase track record

(7%) Avg. Sale Return

(3%) Compound

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	--	--	--	--	--
Purchase Success Rate	--	--	--	--	--
Average Sale Return	5%	25%	39%	25%	(7%)
Sale Success Rate	6 of 6	6 of 6	6 of 6	5 of 6	1 of 6

Revance Therapeutics, Inc.

Drugs » Biotechnology

Principal Accounting Officer:

Holdings: 6.4K shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--